Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
Use of TRIM72 as a Target for Muscle and Heart Enhancer
Korea Health Industry Development Institute (KHIDI) South Korea flag South Korea
Abstract ID:
The muscle enhancer or heart enhancer may be developed into treatments for obesity, type 2 diabetes, muscle disease, cardiac hypertrophy, or the like. And a drug or genetic treatment using TRIM72 can be used for both prevention and treatment....
Contact Yong U Kim
Participants
You
Email me a copy of this message
MECHANISM OF ACTION
Significant use as a target for muscle and heart enhancer efficacies , little or no side effects, plentiful animal data

Technology Platform


The core technology of Korea University is to provide promising target for muscle and heart enhancer, TRIM72.  The TRIM72 exhibits utility as a target for muscle and heart enhancer by distinctly various actions.


Background and unmet needs: A multitue of approaches and researches have been made to prevent and treat obesity, type 2 diabetes, muscle disease, cardiac hypertrophy but have finally failed to find effective growth regulator.  


Discovery and Achievements: Target for muscle and heart enhancer, TRIM72 of Korea University has been developed on the basis of findings that TRIM72 is specifically expressed in lipid rafts of skeletal muscle and heart and results in increased muscle mass during muscle differentiation.


The inventors isolated lipid rafts from C2C12 myoblasts and myotubes, and identified TRIM72, the function of which was never known yet, through comparative proteomics.  TRIM72 has a (ubiquitin E3) TRIM/RBCC domain necessary for ubiquitin E3 ligase activity.  TRIM72 is specifically expressed in lipid rafts of skeletal muscle and heart and results in increased muscle mass during muscle differentiation. TRIM72 overexpression inhibits myogenesis whereas TRIM72 knockdown enhances myogenesis, in other words TRIM72 is a negative regulator of skeletal muscle differentiation.  TRIM72 regulates the IGF-I/IGFR/IRS-1 signaling pathway by inhibiting IGF-I-mediated activation of IRS-1 through interaction with IRS-1.


 Accordingly, TRIM72 acts only on skeletal muscle and heart, without affecting the IGF-I signaling pathway in other tissue.  Therefore, cancer or other side reactions may be prevented.  That is, a drug or genetic treatment using TRIM72 as target may lead to the treatment of obesity and type 2 diabetes without side effects, by promoting differentiation and hypertrophy of skeletal muscle and energy consumption in adipose tissue, and to a strong heart, by promoting physiological hypertrophy of heart muscle.


Key features and advantages:


                     (a)  Significantly increased efficacies


A drug or genetic treatment using TRIM72 as target may lead to the treatment of obesity and type 2 diabetes by promoting differentiation and hypertrophy of skeletal muscle and energy consumption in adipose tissue.


And a drug or genetic treatment using TRIM72 as target may lead to to a strong heart by promoting physiological hypertrophy of heart muscle.


 


(b) Little or no side effects


TRIM72 acts only on skeletal muscle and heart, without affecting the signaling pathway in other tissue.  Therefore, cancer or other side reactions may be prevented.


 


 


 

GO PREMIUM TO GET PATENT INFORMATION
Type of Business Relationship Sought

technology transfer, or non-exclusive or exclusive licensing agreement

FEATURED
Last Updated Jun 2016
Technology Type THERAPEUTIC
Phase of Development EARLY STAGE
GOVERNMENT INSTITUTE